References
- Bartley JM, Cadar AN, Martin DE. 2021. Better, faster, stronger: mRNA vaccines show promise for influenza vaccination in older adults. Immunol Invest. 50(7):810–820. doi:10.1080/08820139.2021.1909617.
- Butterfield R, Dhanani S. 2021. The development of human papillomavirus (HPV) vaccines and current barriers to implementation. Immunol Invest. 50(7):821–832. doi:10.1080/08820139.2021.1897612
- Hajj Hussein I, Chams N, Chams S, El Sayegh S, Badran R, Raad M, Gerges-Geagea A, Leone A, Jurjus A. 2015. Vaccines through centuries: major cornerstones of global health. Front Public Health. 26(3):269. doi:10.3389/fpubh.2015.00269
- Hofman K, Shenoy GN, Chak V, Balu-Iyer SV. 2021. Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines. Immunol Invest. 50(7):743–779. doi:10.1080/08820139.2021.1904977
- Luo W, Yin Q. 2021. B cell response to vaccination. Immunol Invest. 50(7):780–801. doi:10.1080/08820139.2021.1903033
- Mahmoodpoor A, Sanaie S, Samadi P, Yousefi M, Nader ND. 2021 Jun. SARS-CoV-2: unique challenges of the virus and vaccines. Immunol Invest. 50(7):802–809. doi:10.1080/08820139.2021.1936009. PMID: 34109900.
- Mendoza P, Lorenzi JCC, Gaebler C. 2021. COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. Curr Opin HIV AIDS. 16(1):25–35. doi:10.1097/COH.0000000000000657.
- Ostrov BE, Amsterdam D. 2021. Interplay of anti-viral vaccines with biologic agents and immunomodulators in individuals with autoimmune and autoinflammatory diseases. Immunol Invest. 50(7):833–856. doi:10.1080/08820139.2021.1900863
- Reis-Dennis S, Applewhite M. 2021. The ethics of vaccine allocation. Immunol Invest. 50(7):857–867. doi:10.1080/08820139.2021.1924771